Data2Discovery awarded $750,000 NSF SBIR Phase II Grant

Pharmaceutical companies understand there is tremendous potential value locked away in the vast silos of available public and proprietary data. However, this potential is unrealized since the current computation infrastructures are not capable of linking the immense amounts of data together to find key insights.

In March 2017, Data2Discovery was awarded a $750,000 grant from the National Science Foundation (NSF) via the highly competitive Small Business Innovation Research (SBIR) Phase II program to develop the computational infrastructure to address this need. The grant will support Data2Discovery's efforts to support translational and phenotypic research on vast interlinked datasets; which will include applications in Drug Repurposing, Toxicology and Safety, and Phenotypic Analysis.

"Drug Discovery is ripe for disruptive innovation! This grant will enable us to create new data infrastructures that cross preclinical and clinical boundaries in pharma", says Shelley London, Data2Discovery's CEO.

The infrastructure will include a Linked Data Ecosystem (LDE) enabling flexible linking of both public and proprietary data; a computation layer for advanced network analytics; and an interaction layer to enable building specific, fit-for-purpose, end-user solutions.

"The project is utilizing highly-scalable technologies and custom algorithms capable of operating on the vast networks of public and proprietary life sciences data becoming available to drug researchers", says Chief Technology Officer and Principal Investigator for the project, Randy Kerber.

"We are on the verge of a transformational change, where pharmaceutical companies will essentially become data companies", says Dr. David Wild, Data2Discovery’s co-Founder and President, and Associate Professor of Informatics and Computing at Indiana University. "Our technologies are facilitating a completely new way to think about data and how it can be used to drive disease treatment”.

Data2Discovery's business strategy includes empowering industry with faster and more efficient ways to cure specific diseases and find novel therapeutic solutions.


Data2Discovery and OpenPHACTS Foundation announce strategic partnership

The  Open PHACTS Foundation is pleased to formally announce the recent collaboration with Data2Discovery to form a Strategic Partnership.

The goals of the partnership will support and continue with the Open PHACTS vision of creating a sustainable, open, interoperable information infrastructure for applied life science research and development, while advancing science for the public benefit through shared knowledge and data in life science and biomedical research.

Data2Discovery Inc brings extensive experience in pharmaceutical semantic linked data and partners with pharmaceutical companies to develop full-stack semantic and graph capabilities to tackle real scientific problems. 

The Open PHACTS Discovery Platform brings together vast amounts of linked data in a single integrated, open infrastructure providing a platform for researchers to access and query publicly-available pharmacological data.

With input from members and the user community, our collaboration allows us to make considerable efforts to review and refresh the current technical architecture of the Open PHACTS platform, Data & Linksets, APIs, and workflow tools, including Knime and Pipeline Pilot.

The near term goal is to refresh key data sources, including: ChEMBL, Wikipathways, Uniprot and Chemistry, and make those easily available for integration. We encourage and welcome input from the community to streamline the testing experience. We plan further data refreshes of the other data sources over the coming months.

The Open PHACTS Foundation appreciates the fantastic efforts made by the community since inception in 2011, and enthusiastically encourages new involvement which will help steer the future direction of linked data and computational research in academia and industry.

For more information on how to get involved:



Data2Discovery P3 technologies identify potential new drugs for Tuberculosis

Tuberculosis (TB) is a major world health concern, being a declared global emergency and the second most common cause of death from infectious disease globally. In an innovative partnership with the NIH National Center for Advancing Translational Sciences (NCATS), and the OpenPHACTS foundation in the U.K., Data2Discovery Inc has applied its P3 graph-based association finding approach to identify 14 potential drug repurposing opportunities for TB. This small-scale project successfully demonstrated the feasibility of combining two key data resources – EU OpenPHACTS Open Pharmacological Space (OPS) and NCATS Phenotypic Drug Discovery Resource (PDDR) – with state of the art graph mining tools from Data2Discovery. "This proof-of-concept project indicates that a radical new approach to understanding disease and treatment strategies can be highly fruitful", said Dr. David Wild, Founder & President of Data2Discovery. The capabilities demonstrated in this project opens up many opportunities for public impact in rare and neglected diseases, as well as complex disease areas being pursued by pharmaceutical companies.